Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial
Latest Information Update: 15 Apr 2024
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- 08 Apr 2024 Planned End Date changed from 1 Oct 2025 to 1 Jan 2026.
- 08 Apr 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Jul 2025.
- 08 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 1 Jul 2024.